Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Icomidocholic acid - Galmed Pharmaceuticals

Next Previous
Drug Profile

Icomidocholic acid - Galmed Pharmaceuticals

Alternative Names: 3β-arachidylamino-7α,12α-dihydroxy-5β-cholan-24-oic acid; Arachidyl amido cholanoic acid; Aramchol; Aramchol - Galmed Pharmaceuticals; Aramchol meglumine - Galmed Pharmaceuticals

Latest Information Update: 12 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Galmed Medical Research
  • Developer Galmed Medical Research; Galmed Pharmaceuticals; University of California, San Diego
  • Class Anti-inflammatories; Antifibrotics; Antineoplastics; Bile acids and salts; Cholic acids; Drug conjugates; Eicosanoic acids; Eicosanoids; Fatty acids; Gallstone therapies; Hepatoprotectants; Small molecules
  • Mechanism of Action Autophagy stimulants; Stearoyl-CoA desaturase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Lipodystrophy; Non-alcoholic steatohepatitis

Highest Development Phases

  • Phase III Fibrosis; Non-alcoholic steatohepatitis
  • Phase II Cholelithiasis; Lipodystrophy; Non-alcoholic fatty liver disease
  • Preclinical Cancer; Inflammatory bowel diseases; Primary sclerosing cholangitis

Most Recent Events

  • 04 Dec 2025 Galmed Pharmaceuticals has patent protection for use of a combination therapy of Aramchol and Rezdiffra for the treatment of non-alcoholic steatohepatitis and liver fibrosis in South Korea
  • 01 Dec 2025 Galmed Pharmaceuticals plans a phase I/II trial for Colorectal cancer (CRC), Hepatocellular carcinoma (HCC), and Cholangiocarcinoma in early 2026
  • 01 Dec 2025 Galmed Pharmaceuticals plans a phase II trial for Non-alcoholic-steatohepatitis (Combination therapy)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top